Aqilion AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aqilion.com
Clinical Trials
3
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Not Applicable
1 (33.3%)Comparing the Extent to Which AQ280 is Made Available in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
Not Applicable
Completed
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Drug: Placebo CapsuleDrug: AQ280 CapsuleDrug: Placebo Tablet for Oral SuspensionDrug: AQ280 Tablet for Oral Suspension
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- AQILION AB
- Target Recruit Count
- 9
- Registration Number
- NCT07093008
- Locations
- 🇺🇸
Clinical Research Site, Madison, Wisconsin, United States
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- AQILION AB
- Target Recruit Count
- 66
- Registration Number
- NCT05485779
- Locations
- 🇬🇧
Fortrea Clinical Research Unit Ltd., Leeds, United Kingdom
News
No news found